Yahoo Search Busca da Web

Resultado da Busca

  1. Latest enhanced and revised set of guidelines. ESMO has Clinical Practice Guidelines on the following Gastrointestinal Cancers: Rectal Cancer, Biliary cancer, Gastric cancer, Oesophageal cancer, Pancreatic cancer, Metastatic colorectal cancer, Anal cancer, Early colon cancer, Familial risk colorectal cancer, Hepatocellular carcinoma.

  2. Treatment of Metastatic Colorectal Cancer: ASCO Guideline October 17, 2022. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update December 22, 2021. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline June 22, 2020. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update June 10, 2019

  3. 2 de mar. de 2021 · Abstract. This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section.

    • Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi Jen Chen, Kristen K. Ciombo...
    • 2021
  4. Guideline PDF. 2023 Clinical Practice Guidelines. Management of Rectal Cancer 2023 Supplement to 2020 Rectal Cancer CPG. Podcast | Visual Abstract. Reduction of Venous Thromboembolic Disease in Colorectal Surgery. Guideline PDF | Podcast | Visual Abstract. Management of Fecal Incontinence. Guideline PDF | Podcast | Visual Abstract.

  5. 25 de out. de 2022 · This ESMO Clinical Practice Guideline provides key recommendations for managing metastatic colorectal cancer. •. It covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. •. Treatment algorithms for locoregional, advanced/metastatic and recurrent advanced colorectal cancer are provided. •.

  6. 17 de out. de 2022 · Guideline Question. What is the recommended treatment for metastatic colorectal cancer (mCRC)? Target Population.

  7. The 5-year overall survival for patients with localized, regional, and metastatic colon cancer is 91%, 72%, and 13%.2 The scope of this guideline is to address the issues re-lated to the evaluation and treatment of patients who have been diagnosed with colon cancer.

    • 195KB
    • 19